AU2014306564B2 - Antibodies against frizzled proteins and methods of use thereof - Google Patents

Antibodies against frizzled proteins and methods of use thereof Download PDF

Info

Publication number
AU2014306564B2
AU2014306564B2 AU2014306564A AU2014306564A AU2014306564B2 AU 2014306564 B2 AU2014306564 B2 AU 2014306564B2 AU 2014306564 A AU2014306564 A AU 2014306564A AU 2014306564 A AU2014306564 A AU 2014306564A AU 2014306564 B2 AU2014306564 B2 AU 2014306564B2
Authority
AU
Australia
Prior art keywords
region
cdr
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014306564A
Other languages
English (en)
Other versions
AU2014306564A1 (en
Inventor
Stephane ANGERS
Amandeep GAKHAL
Jason MOFFAT
Guohua Pan
Melanie ROBITAILLE
Sachdev Sidhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AntlerA Therapeutics Inc
Original Assignee
AntlerA Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AntlerA Therapeutics Inc filed Critical AntlerA Therapeutics Inc
Publication of AU2014306564A1 publication Critical patent/AU2014306564A1/en
Application granted granted Critical
Publication of AU2014306564B2 publication Critical patent/AU2014306564B2/en
Priority to AU2019264562A priority Critical patent/AU2019264562B2/en
Assigned to SIDHU, SACHDEV, MOFFAT, Jason, ANGERS, Stephane, ROBITAILLE, Melanie reassignment SIDHU, SACHDEV Request for Assignment Assignors: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Assigned to MODMAB THERAPEUTICS CORPORATION reassignment MODMAB THERAPEUTICS CORPORATION Request for Assignment Assignors: ANGERS, Stephane, MOFFAT, Jason, ROBITAILLE, Melanie, SIDHU, SACHDEV
Assigned to ANTLERA THERAPEUTICS INC. reassignment ANTLERA THERAPEUTICS INC. Request for Assignment Assignors: MODMAB THERAPEUTICS CORPORATION
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2014306564A 2013-08-14 2014-08-14 Antibodies against frizzled proteins and methods of use thereof Active AU2014306564B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019264562A AU2019264562B2 (en) 2013-08-14 2019-11-12 Antibodies against frizzled proteins and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361865668P 2013-08-14 2013-08-14
US61/865,668 2013-08-14
PCT/US2014/051070 WO2015023851A1 (en) 2013-08-14 2014-08-14 Antibodies against frizzled proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019264562A Division AU2019264562B2 (en) 2013-08-14 2019-11-12 Antibodies against frizzled proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2014306564A1 AU2014306564A1 (en) 2016-03-03
AU2014306564B2 true AU2014306564B2 (en) 2019-10-17

Family

ID=51398950

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014306564A Active AU2014306564B2 (en) 2013-08-14 2014-08-14 Antibodies against frizzled proteins and methods of use thereof
AU2019264562A Active AU2019264562B2 (en) 2013-08-14 2019-11-12 Antibodies against frizzled proteins and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019264562A Active AU2019264562B2 (en) 2013-08-14 2019-11-12 Antibodies against frizzled proteins and methods of use thereof

Country Status (6)

Country Link
US (2) US10077304B2 (cg-RX-API-DMAC7.html)
EP (2) EP3033356B1 (cg-RX-API-DMAC7.html)
JP (3) JP6617239B2 (cg-RX-API-DMAC7.html)
AU (2) AU2014306564B2 (cg-RX-API-DMAC7.html)
CA (1) CA2921398C (cg-RX-API-DMAC7.html)
WO (1) WO2015023851A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014306564B2 (en) * 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2017127933A1 (en) 2016-01-29 2017-08-03 The Governing Council Of The University Of Toronto Frizzled protein-binding agents and methods of use thereof
JP2019534858A (ja) * 2016-09-09 2019-12-05 ジェネンテック, インコーポレイテッド Frizzledの選択的ペプチド阻害剤
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7418332B2 (ja) * 2017-12-19 2024-01-19 スロゼン オペレーティング, インコーポレイテッド 抗フリズルド抗体及び使用方法
US20210032352A1 (en) * 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
AU2019297522B2 (en) 2018-07-05 2026-04-23 Surrozen Operating, Inc. Multi-specific Wnt surrogate molecules and uses thereof
KR20220024460A (ko) * 2019-06-11 2022-03-03 안틀라 테라퓨틱스 아이엔씨. 다가 fzd 및 wnt 결합 분자 및 이의 용도
CN114616246B9 (zh) * 2019-08-12 2026-06-23 安托拉诊疗公司 卷曲受体抗体及其用途
CN112159474B (zh) * 2019-11-06 2021-11-19 上海健康医学院 一种靶向Frizzled7人源化抗体及其制备方法与应用
CA3204321A1 (en) 2020-12-18 2022-06-23 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023250402A2 (en) 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
CA3244362A1 (en) * 2022-02-18 2023-08-24 The University Of Chicago Growth hormone receptor polypeptides
US20260092125A1 (en) 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof
US20260070966A1 (en) 2024-09-06 2026-03-12 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037041A2 (en) * 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5203778A (en) 1986-02-18 1993-04-20 Boehringer Laboratories Process and apparatus for removal of insoluble fat from blood of a patient
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
WO1993016043A1 (en) 1992-02-18 1993-08-19 Otsuka Kagaku Kabushiki Kaisha β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN102971337B (zh) * 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
EP2720721B1 (en) * 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
EP2761064B1 (en) * 2011-09-27 2021-04-28 The Governing Council Of The University Of Toronto Molecular display method
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037041A2 (en) * 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof

Also Published As

Publication number Publication date
EP3033356A1 (en) 2016-06-22
EP3033356B1 (en) 2020-01-15
WO2015023851A1 (en) 2015-02-19
JP7393447B2 (ja) 2023-12-06
US10077304B2 (en) 2018-09-18
JP2016528256A (ja) 2016-09-15
JP2022105495A (ja) 2022-07-14
CA2921398C (en) 2021-12-14
EP3705494A2 (en) 2020-09-09
JP7100221B2 (ja) 2022-07-13
US20190202909A1 (en) 2019-07-04
CA2921398A1 (en) 2015-02-19
AU2014306564A1 (en) 2016-03-03
JP2020023517A (ja) 2020-02-13
US20160194394A1 (en) 2016-07-07
JP6617239B2 (ja) 2019-12-11
AU2019264562A1 (en) 2019-12-05
AU2019264562B2 (en) 2022-01-13
US10689442B2 (en) 2020-06-23
EP3705494A3 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
US10689442B2 (en) Antibodies against Frizzled receptor
CN111629754B (zh) 不引起显著红血细胞凝集的抗cd47抗体
US20210371522A1 (en) Cd47 antibodies and methods of use thereof
US20210317205A1 (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
EP2953643B1 (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US20140140989A1 (en) Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
CA2724279A1 (en) Anti-il-6/il-6r antibodies and methods of use thereof
US20220315655A1 (en) Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
HK1225042B (en) Antibodies against frizzled proteins and methods of use thereof
HK1225042A1 (en) Antibodies against frizzled proteins and methods of use thereof
HK40088423A (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
HK40018837A (en) Cd47 antibodies and methods of use thereof
HK1205195B (en) Cd47 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MOFFAT, JASON

Free format text: FORMER APPLICANT(S): THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

Owner name: SIDHU, SACHDEV

Free format text: FORMER APPLICANT(S): THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

Owner name: ROBITAILLE, MELANIE

Free format text: FORMER APPLICANT(S): THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

Owner name: ANGERS, STEPHANE

Free format text: FORMER APPLICANT(S): THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MODMAB THERAPEUTICS CORPORATION

Free format text: FORMER OWNER(S): ANGERS, STEPHANE; ROBITAILLE, MELANIE; MOFFAT, JASON; SIDHU, SACHDEV

PC Assignment registered

Owner name: ANTLERA THERAPEUTICS INC.

Free format text: FORMER OWNER(S): MODMAB THERAPEUTICS CORPORATION